MDX-240: Began Phase I/II trial

Medarex Inc. (MEDX), Princeton, N.J. Product: MDX-240, a Bi-specific antibody that targets the gp41 protein of HIV expressed on infected cells, coupled to an antibody that triggers killer cells Indica...